TScan Therapeutics Q3 2026 Results: Net Loss of $33.1M, Loss Narrows
TScan Therapeutics reports significant ongoing losses and has identified conditions raising substantial doubt about its ability to continue as a going concern. The company is currently non-compliant with Nasdaq's continued listing requirements and requires substantial additional funding to advance its TCR-T therapy product candidates through clinical development.
- Key figure
- Net loss $33.1M